상세 보기
Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study
- Ozguroglu, M.;
- Ahn, M-J.;
- Dong, X.;
- Yang, J. C-H.;
- Oizumi, S.;
- 외 11명
Citations
WEB OF SCIENCE
2- 제목
- Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study
- 저자
- Ozguroglu, M.; Ahn, M-J.; Dong, X.; Yang, J. C-H.; Oizumi, S.; Goto, K.; Cobo Dols, M.; Kim, S-W.; Hsia, T-C.; Chindaprasirt, J.; Fujiki, F. K.; Valdiviezo, N.; Poole, L.; Evans, A. L.; Armenteros Monterroso, E.; Lu, S.
- 발행일
- 2024-12
- 유형
- Meeting Abstract
- 권
- 35
- 페이지
- S1626 ~ S1626